Group 1 - The company reported a revenue of RMB 31.834 billion for the year ending December 31, 2025, representing a year-on-year increase of 10.25% [2] - The net profit attributable to the parent company was RMB 2.343 billion, a decrease of 33.04% year-on-year, with basic earnings per share at RMB 0.1302 [2] - The company plans to distribute a final dividend of HKD 0.05 per share [2] Group 2 - The company has entered a period of intensive harvest for innovative products, having received approvals for 16 innovative products over the past three years (2023-2025), including 7 Class 1 innovative drugs [2] - Four innovative products were approved for market launch by NMPA during the reporting period, including Saitanxin, Shenghetu, Putanning, and Anqixin [2] - The revenue from innovative products is expected to reach RMB 15.22 billion in 2025, reflecting a year-on-year growth of 26.2% [2] Group 3 - Research and development (R&D) is the core driving force for the company, which views it as the foundation for sustainable development [3] - The company has established multiple R&D centers in cities such as Shanghai, Nanjing, Beijing, and Guangzhou, and has developed a diversified innovation technology platform [3] - Total R&D investment for the year ending December 31, 2025, was approximately RMB 6.317 billion, accounting for about 19.8% of the company's revenue, with 92.9% of this amount recognized in the profit and loss statement [3]

Group 1 - The company reported a revenue of RMB 31.834 billion for the year ending December 31, 2025, representing a year-on-year increase of 10.25% [1] - The profit attributable to the parent company was RMB 2.343 billion, a decrease of 33.04% year-on-year, with basic earnings per share at RMB 0.1302 [1] - The company plans to distribute a final dividend of HKD 0.05 per share [1] Group 2 - The company has entered a period of intensive harvest of innovative products, having received approvals for 16 innovative products over the past three years (2023-2025), including 7 Class 1 innovative drugs [1] - Four innovative products were approved for market launch by NMPA during the reporting period, including Saitanxin, Shenghetu, Putanning, and Anqixin [1] - The revenue from innovative products is expected to reach RMB 15.22 billion in 2025, reflecting a year-on-year growth of 26.2% [1] Group 3 - Research and development (R&D) is the core driving force for the company, which views it as the foundation for sustainable development [2] - The company has established multiple R&D centers in cities such as Shanghai, Nanjing, Beijing, and Guangzhou, creating a diversified innovation technology platform [2] - Total R&D investment for the year ending December 31, 2025, was approximately RMB 6.317 billion, accounting for about 19.8% of the company's revenue, with 92.9% of this amount recognized in the profit and loss statement [2]